The 'Peptide for Life' Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe

Antoni Bayes-Genis; James L Januzzi; A Mark Richards; Henrike Arfsten; Rudolf A de Boer; Michele Emdin; Arantxa González; Tiny Jaarsma; Pardeep S Jhund; Christian Mueller; Julio Núñez; Patrick Rossignol; Ivan Milinkovic; Giuseppe M C Rosano; Andrew Coats; Petar Seferovic

doi:10.1002/ejhf.2293

The 'Peptide for Life' Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe

Antoni Bayes-Genis^*, James L Januzzi, A Mark Richards, Henrike Arfsten, Rudolf A de Boer, Michele Emdin, Arantxa González, Tiny Jaarsma, Pardeep S Jhund, Christian Mueller, Julio Núñez, Patrick Rossignol, Ivan Milinkovic, Giuseppe M C Rosano, Andrew Coats, Petar Seferovic

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1432-1436
Number of pages	5
Journal	European Journal of Heart Failure
Volume	23
Issue number	9
DOIs	https://doi.org/10.1002/ejhf.2293
Publication status	Published - Sept 2021
Externally published	Yes

Keywords

Atrial Natriuretic Factor
Biomarkers
Europe
Heart Failure/diagnosis
Humans
Natriuretic Peptide, Brain
Natriuretic Peptides
Peptide Fragments
Peptides

Access to Document

10.1002/ejhf.2293

Cite this

Bayes-Genis, A., Januzzi, J. L., Richards, A. M., Arfsten, H., de Boer, R. A., Emdin, M., González, A., Jaarsma, T., Jhund, P. S., Mueller, C., Núñez, J., Rossignol, P., Milinkovic, I., Rosano, G. M. C., Coats, A., & Seferovic, P. (2021). The 'Peptide for Life' Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. European Journal of Heart Failure, 23(9), 1432-1436. https://doi.org/10.1002/ejhf.2293

@article{c4949c61dfc345caaea8934562052100,

title = "The 'Peptide for Life' Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe",

keywords = "Atrial Natriuretic Factor, Biomarkers, Europe, Heart Failure/diagnosis, Humans, Natriuretic Peptide, Brain, Natriuretic Peptides, Peptide Fragments, Peptides",

author = "Antoni Bayes-Genis and Januzzi, {James L} and Richards, {A Mark} and Henrike Arfsten and {de Boer}, {Rudolf A} and Michele Emdin and Arantxa Gonz{\'a}lez and Tiny Jaarsma and Jhund, {Pardeep S} and Christian Mueller and Julio N{\'u}{\~n}ez and Patrick Rossignol and Ivan Milinkovic and Rosano, {Giuseppe M C} and Andrew Coats and Petar Seferovic",

note = "Funding Information: : A.B.G. reports grants and personal fees from AstraZeneca, Abbott, Vifor, Boehringer Ingelheim, Novartis, Roche Diagnostics and Critical Diagnostics. J.L.J. is a trustee of the American College of Cardiology, a board member of Imbria Pharmaceuticals, has received grant support from Applied Therapeutics, Innolife, Novartis Pharmaceuticals and Abbott Diagnostics, consulting income from Abbott, Janssen, Novartis, and Roche Diagnostics, and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, Bayer, CVRx, Janssen, MyoKardia and Takeda. A.M.R. declares grants (including support in kind) and/or personal fees (researcher, speaker, advisory board member) from Roche Diagnostics, Abbott Laboratories, Thermo Fisher, Boston Scientific, Novartis, AstraZeneca, Sphingotec, Bayer and Critical Diagnostics. The UMCG, which employs R.A.d.B., has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. R.A.d.B. received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. P.S.J. is an employer of the University of Glasgow and has been remunerated by Novartis, Novo Nordisk and AstraZeneca for his work on clinical trials and he has received speakers fees and/or advisory board fees from Novartis, AstraZeneca, Boehringer Ingelheim and grants from Boehringer Ingelheim. C.M. has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the European Union, the University of Basel, the University Hospital Basel, Abbott, Beckman Coulter, BRAHMS, Idorsia, Novartis, Ortho Clinical Diagnostics, Quidel, Roche, Siemens, Singulex, Sphingotec, as well as speaker honoraria/consulting honoraria from Acon, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Idorsia, Novartis, Osler, Roche, and Sanofi outside of the submitted work. J.N. reports speaker fees and/or advisory board fees from AstraZeneca, Novartis, Vifor Pharma, Boehringer Ingelheim, Novo Nordisk, Rovi, Bayer, and Pfizer. P.R. reports consulting for Bayer, G3P, Idorsia, and KBP; honoraria from Ablative Solutions, AstraZeneca, Bayer, Boehringer Ingelheim, Corvidia, CVRx, Fresenius, Grunenthal, Novartis, Novo Nordisk, Relypsa Inc., a Vifor Pharma Group Company, Sanofi, Sequana Medical, Servier, Stealth Peptides, and Vifor Fresenius Medical Care Renal Pharma; co‐founder: CardioRenal. A.C. declares having received honoraria and/or lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, Novartis, Nutricia, Servier, Vifor, Abbott, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Gore, Impulse Dynamics, Respicardia. All other authors have nothing to disclose. Conflict of interest",

year = "2021",

month = sep,

doi = "10.1002/ejhf.2293",

language = "English",

volume = "23",

pages = "1432--1436",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Oxford University Press",

number = "9",

}

Bayes-Genis, A, Januzzi, JL, Richards, AM, Arfsten, H, de Boer, RA, Emdin, M, González, A, Jaarsma, T, Jhund, PS, Mueller, C, Núñez, J, Rossignol, P, Milinkovic, I, Rosano, GMC, Coats, A & Seferovic, P 2021, 'The 'Peptide for Life' Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe', European Journal of Heart Failure, vol. 23, no. 9, pp. 1432-1436. https://doi.org/10.1002/ejhf.2293

The 'Peptide for Life' Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. / Bayes-Genis, Antoni; Januzzi, James L; Richards, A Mark et al.
In: European Journal of Heart Failure, Vol. 23, No. 9, 09.2021, p. 1432-1436.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The 'Peptide for Life' Initiative

T2 - a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe

AU - Bayes-Genis, Antoni

AU - Januzzi, James L

AU - Richards, A Mark

AU - Arfsten, Henrike

AU - de Boer, Rudolf A

AU - Emdin, Michele

AU - González, Arantxa

AU - Jaarsma, Tiny

AU - Jhund, Pardeep S

AU - Mueller, Christian

AU - Núñez, Julio

AU - Rossignol, Patrick

AU - Milinkovic, Ivan

AU - Rosano, Giuseppe M C

AU - Coats, Andrew

AU - Seferovic, Petar

N1 - Funding Information: : A.B.G. reports grants and personal fees from AstraZeneca, Abbott, Vifor, Boehringer Ingelheim, Novartis, Roche Diagnostics and Critical Diagnostics. J.L.J. is a trustee of the American College of Cardiology, a board member of Imbria Pharmaceuticals, has received grant support from Applied Therapeutics, Innolife, Novartis Pharmaceuticals and Abbott Diagnostics, consulting income from Abbott, Janssen, Novartis, and Roche Diagnostics, and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, Bayer, CVRx, Janssen, MyoKardia and Takeda. A.M.R. declares grants (including support in kind) and/or personal fees (researcher, speaker, advisory board member) from Roche Diagnostics, Abbott Laboratories, Thermo Fisher, Boston Scientific, Novartis, AstraZeneca, Sphingotec, Bayer and Critical Diagnostics. The UMCG, which employs R.A.d.B., has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. R.A.d.B. received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. P.S.J. is an employer of the University of Glasgow and has been remunerated by Novartis, Novo Nordisk and AstraZeneca for his work on clinical trials and he has received speakers fees and/or advisory board fees from Novartis, AstraZeneca, Boehringer Ingelheim and grants from Boehringer Ingelheim. C.M. has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the European Union, the University of Basel, the University Hospital Basel, Abbott, Beckman Coulter, BRAHMS, Idorsia, Novartis, Ortho Clinical Diagnostics, Quidel, Roche, Siemens, Singulex, Sphingotec, as well as speaker honoraria/consulting honoraria from Acon, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Idorsia, Novartis, Osler, Roche, and Sanofi outside of the submitted work. J.N. reports speaker fees and/or advisory board fees from AstraZeneca, Novartis, Vifor Pharma, Boehringer Ingelheim, Novo Nordisk, Rovi, Bayer, and Pfizer. P.R. reports consulting for Bayer, G3P, Idorsia, and KBP; honoraria from Ablative Solutions, AstraZeneca, Bayer, Boehringer Ingelheim, Corvidia, CVRx, Fresenius, Grunenthal, Novartis, Novo Nordisk, Relypsa Inc., a Vifor Pharma Group Company, Sanofi, Sequana Medical, Servier, Stealth Peptides, and Vifor Fresenius Medical Care Renal Pharma; co‐founder: CardioRenal. A.C. declares having received honoraria and/or lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, Novartis, Nutricia, Servier, Vifor, Abbott, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Gore, Impulse Dynamics, Respicardia. All other authors have nothing to disclose. Conflict of interest

PY - 2021/9

Y1 - 2021/9

KW - Atrial Natriuretic Factor

KW - Biomarkers

KW - Europe

KW - Heart Failure/diagnosis

KW - Humans

KW - Natriuretic Peptide, Brain

KW - Natriuretic Peptides

KW - Peptide Fragments

KW - Peptides

UR - http://www.scopus.com/inward/record.url?scp=85110346515&partnerID=8YFLogxK

U2 - 10.1002/ejhf.2293

DO - 10.1002/ejhf.2293

M3 - Article

C2 - 34231321

SN - 1388-9842

VL - 23

SP - 1432

EP - 1436

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 9

ER -

The 'Peptide for Life' Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe

Keywords

Access to Document

Other files and links

Cite this